Contraception
Volume 78, Issue 5 , Pages 377-383 , November 2008

Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives

  • Jeanne Loughlin

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 781 472 8460; fax: +1 781 472 8464.
    • ,
  • John D. Seeger

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    • ,
  • P. Mona Eng

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Marie Foegh

      Affiliations

    • Division of Nephrology, Department of Medicine, Georgetown University Medical School, Washington, DC 20057, USA
    • Agile Therapeutics, Inc., Princeton, NJ 08540, USA
    • ,
  • C. Robin Clifford

      Affiliations

    • Ingenix i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Jennifer Cutone

      Affiliations

    • Veristat, Inc., Holliston, MA 01746, USA
    • ,
  • Alexander M. Walker

      Affiliations

    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    • World Health Information Science Consultants, LLC, Wellesley, MA 02481, USA

Received 10 April 2008 ,Revised 26 June 2008 ,Accepted 27 June 2008.

References 

  1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717
  2. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  3. Juurlink DN, Muhammad MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543–551
  4. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;12:716–727
  5. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18:797–804
  6. Jessup M. Aldosterone blockade and heart failure. N Engl J Med. 2003;348:1380–1382
  7. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55
  8. Joffee MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333
  9. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–763
  10. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249–264
  11. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Safety. 2005;14:465–476
  12. Rothman KJ. Epidemiology. An introduction. New York (NY): Oxford University Press; 2002;
  13. Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med. 1992;22:351–361
  14. SAS/STAT, Version 8.2. Cary (NC): SAS Institute; 2001;
  15. Stata Statistical Software: Release 6. College Station (Tex): StataCorp LP; 1999;
  16. Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplemental data collection with case-cohort analysis to address confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Safety. 2008;17:297–305
  17. Shah KB, Krishnamurti R, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845–849
  18. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. J Card Fail. 2004;10:297–303
  19. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin–angiotensin–aldosterone system. N Engl J Med. 2004;351:585–592
  20. McMurray JJV, O'Meara E. Treatment of heart failure with spironolactone — trial and tribulations. N Engl J Med. 2004;351:526–528
  21. Heinemann LAJ, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Safety. 2004;27:1001–1018
  22. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2003;(4):CD000194

☆ This study was funded by a research contract between Ingenix i3 Drug Safety and Berlex (now a unit of Bayer Health Care). The contract granted i3 Drug Safety oversight of the study conduct, reporting and interpretation, as well as final wording of any resulting manuscripts.

PII: S0010-7824(08)00342-9

doi: 10.1016/j.contraception.2008.06.012

Contraception
Volume 78, Issue 5 , Pages 377-383 , November 2008

Article Tools

* Image Usage & Resolution